William F Maguire
Overview
Explore the profile of William F Maguire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brave M, Maguire W, Weinstock C, Zhang H, Gao X, Li F, et al.
Clin Cancer Res
. 2024 Sep;
30(21):4815-4821.
PMID: 39230571
On December 15, 2023, the FDA granted traditional approval to enfortumab vedotin-ejfv plus pembrolizumab (EV + Pembro) for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Substantial evidence of...
2.
Fallah J, Xu J, Joeng H, Weinstock C, Heiss B, Maguire W, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2400354.
PMID: 39208375
False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.
3.
Fallah J, Xu J, Weinstock C, Gao X, Heiss B, Maguire W, et al.
J Clin Oncol
. 2024 Mar;
42(14):1687-1698.
PMID: 38484203
Purpose: We performed a pooled analysis of multiple trials of poly(ADP-ribose) polymerase inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) to investigate the efficacy of PARPi in each individual homologous...
4.
Maguire W, Lee D, Weinstock C, Gao X, Bulik C, Agrawal S, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2011-2016.
PMID: 38441576
On April 3, 2023, the FDA granted accelerated approval to enfortumab vedotin-ejfv (EV) plus pembrolizumab for treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for...
5.
Maguire W, Haley P, Dietz C, Hoffelder M, Brandt C, Joyce R, et al.
JID Innov
. 2023 Mar;
3(2):100181.
PMID: 36960318
The documentation of the change in the number and appearance of pigmented cutaneous lesions over time is critical to the early detection of skin cancers and may provide preliminary signals...
6.
Maguire W, Schmitz J, Scemama J, Czambel K, Lin Y, Green A, et al.
Cancer Chemother Pharmacol
. 2021 Jun;
88(4):643-654.
PMID: 34164713
Purpose: We investigated the combination of tivantinib, a c-MET tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-VEGF-A antibody. Methods: Patients with advanced solid tumors received bevacizumab (10 mg/kg intravenously every...
7.
8.
Behling K, Maguire W, Di Gialleonardo V, Heeb L, Hassan I, Veach D, et al.
J Nucl Med
. 2016 Jun;
57(11):1771-1777.
PMID: 27261519
Methods: We investigated remodeling of the tumor microenvironment in transgenic Ntva glioblastoma mice using a therapeutic 7.4-kBq dose of Ac-E4G10. Immunofluorescence and immunohistochemical analyses imaged morphologic changes in the tumor...
9.
Behling K, Maguire W, Lopez Puebla J, Sprinkle S, Ruggiero A, ODonoghue J, et al.
J Nucl Med
. 2016 Apr;
57(10):1576-1582.
PMID: 27127217
Methods: E4G10, an antibody directed at an epitope of monomeric vascular endothelium cadherin that is expressed in tumor neovasculature and on endothelial progenitor cells in the bone marrow, was labeled...
10.
Villa J, Chiu D, Brandes A, Escorcia F, Villa C, Maguire W, et al.
Cell Rep
. 2014 Aug;
8(4):1077-92.
PMID: 25131208
γ-Secretase is composed of four proteins that are obligatory for protease activity: presenilin, nicastrin, Aph1, and Pen-2. Despite the progress toward understanding the function of these individual subunits, there is...